Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin

(2012) C. Jovelet et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study

(2011) Li Zhang et al.   CLINICAL THERAPEUTICS

The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy

(2011) Chung-Pu Wu et al.   MOLECULAR PHARMACEUTICS

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

(2009) Amalia Azzariti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function

(2009) Li-sheng Zheng et al.   PLoS One

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

(2008) S. Marchetti et al.   MOLECULAR CANCER THERAPEUTICS